Article Abstract

Cytoreductive surgery in the era of targeted molecular therapy

Authors: Arun Z. Thomas, Mehrad Adibi, Leonardo D. Borregales, Jose A. Karam, Christopher G. Wood

Abstract

Cytoreductive nephrectomy (CN) was regarded standard of care for patients with metastatic renal cell carcinoma (mRCC) in the immunotherapy era. With the advent of targeted molecular therapy (TMT) for the treatment of mRCC, the routine use of CN has been questioned. Up to date evidence continues to suggest that CN remains an integral part of treatment in appropriately selected patients. This review details the original context in which the efficacy of CN was established and rationale for the continued use of cytoreductive surgery in the era of TMT.